EQUISUL-SDT® is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subsp. zooepidemicus. EQUISUL-SDT® is produced using Aurora Pharmaceutical’s patented drug product formulation. The product demonstrated 20% increased bioavailability over an existing paste product in a pharmacokinetic crossover study.
Safety was demonstrated in a controlled study in horses at 1X, 3X and 5X the recommended dose for 30 days
Low incidence of side effects in controlled safety studies
Easy-to-use, apple-flavored liquid formulation
Significantly higher bioavailability on a mg-to-mg basis compared to an approved paste product, based on a pharmacokinetic crossover study
